Journal
THERANOSTICS
Volume 8, Issue 15, Pages 4238-4246Publisher
IVYSPRING INT PUBL
DOI: 10.7150/thno.24387
Keywords
Neoantigen; vaccine; immunotherapy; T-cell response
Categories
Funding
- National Key Research and Development Program of China [2017YFC1308900]
- Key Research and Development Program of Jiangsu Province [BE2017607]
- Jiangsu Provincial Medical Youth Talent [QNRC2016045]
Ask authors/readers for more resources
Cancer vaccines have encountered their ideal personalized partner along with evidence for great breakthroughs in the identification and synthesis of neoantigens. Individual cancer neoantigen vaccines are capable of eliciting robust T-cell responses and have been demonstrated to achieve striking clinical efficacy due to their high immunogenicity and central thymic tolerance escape of neoantigens. Two recent phase I clinical trials have provided support for the hypothesis and have heralded a nascent era of personalized vaccines in the field of immunotherapy. This review aims to address the identification of neoepitopes and describes advances made in personalized vaccines. In addition, this review discusses the challenges related to the exploitation of vaccine therapy, and provides potential thoughts for the improvement of vaccine design and applications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available